Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been the only method for curing many hematopoietic benign or malignant diseases, from which a number of patients obtain long-term survival. However, graft versus host disease (GVHD) deeply hinders the development and clinical use of HSCT. Up to now, immune response triggered by donor's T cell has been considered to be the pathogenesis of GVHD. On the other side, donor's T cell has indispensable effect in competing with the tumor cells and reducing the disease recurrence rate. So, how to prevent GVHD, meanwhile, to retain graft versus tumor (GVT) effect, has become one of the challenging problems after HSCT. Recently, drugs such as trametinib and echinomycin, expanding regulatory T cells in vitro and advanced techniques such as conformal nanoencapsulation have shown optimistic results in experiments of separating GVHD and GVT effect, which are hopefully to be utilized in clinic in the future.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
